6:49 PM
 | 
Mar 07, 2008
 |  BC Extra  |  Company News

FDA posts Bridion briefing documents

FDA will ask an advisory panel on Tuesday whether the primary endpoint used in trials of Bridion sugammadex has clinical relevance. According to briefing documents released ahead of the meeting of FDA's Anesthetic and Life Support Drugs Advisory Committee, the agency also will ask whether risks have been adequately characterized for adult patients receiving Bridion, including...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >